Tarsus Pharmaceuticals, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Oppenheimer's Fall 2026 SMID-cap stock picks include four Strong Buy-rated companies: Semtech (SMTC, 4.96), Onto Innovation (ONTO, 4.83), Life Time Group (LTH, 4.72), and Pursuit Attractions (PRSU, 4.61). The remaining nine stocks received Hold ratings, with scores ranging from 3.48 to 2.78. Seeking Alpha's Quant Rating system evaluates stocks on valuation, growth, profitability, and momentum.
Analysts updated ratings for healthcare companies. TD Cowen maintained a Buy rating on TransMedics Group (TMDX) with a $120 target. Regeneron (REGN) was kept at Hold by Leerink Partners. Oppenheimer maintained a Buy rating on Tarsus Pharmaceuticals (TARS) with a $100 target. All have consensus ratings and price targets.
Goldman Sachs initiated coverage of Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy rating and $116.00 price target. The company's stock trades at $74.29 with a $3.26B market cap. Tarsus reported Q2 2026 sales of $173.9M, beating estimates, and raised full-year Xdemvy sales guidance. Jefferies raised its price target to $105, citing strong prescription data.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning TARS (Tarsus Pharmaceuticals, Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent TARS coverage spans financial news, insider activity and mergers & acquisitions.
In the last 30 days, TARS insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($980K). The most active reporter was LINK WILLIAM J PHD with 3 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Bearish rating could weigh on the stock.
Buy rating with a higher target may encourage modest buying.
Analyst upgrade may lift the stock toward the new target.
Insider sale may signal lack of confidence, could pressure stock short-term.
Analyst upgrade signals expected outperformance and may drive short‑term buying pressure.
AlphAI scores every news story that mentions TARS with an AI model for sentiment and relevance, and aggregates insider trades from Tarsus Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Oppenheimer's Fall 2026 SMID-cap stock picks include four Strong Buy-rated companies: Semtech (SMTC, 4.96), Onto Innovation (ONTO, 4.83), Life Time Group (LTH, 4.72), and Pursuit Attractions (PRSU, 4.61). The remaining nine stocks received Hold ratings, with scores ranging from 3.48 to 2.78. Seeking Alpha's Quant Rating system evaluates stocks on valuation, growth, profitability, and momentum.
2 min readAnalysts updated ratings for healthcare companies. TD Cowen maintained a Buy rating on TransMedics Group (TMDX) with a $120 target. Regeneron (REGN) was kept at Hold by Leerink Partners. Oppenheimer maintained a Buy rating on Tarsus Pharmaceuticals (TARS) with a $100 target. All have consensus ratings and price targets.
2 min readGoldman Sachs initiated coverage of Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy rating and $116.00 price target. The company's stock trades at $74.29 with a $3.26B market cap. Tarsus reported Q2 2026 sales of $173.9M, beating estimates, and raised full-year Xdemvy sales guidance. Jefferies raised its price target to $105, citing strong prescription data.
2 min readLINK WILLIAM J PHD sold 12,500 shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $78.38 ($78.33–$80.01, $0.98M total) across 3 trades on 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readBarclays reinstated Tarsus Pharmaceuticals (TARS) with an Overweight rating and a $110.00 price target. The company's stock is currently trading at $78.23, with a GF Value™ of $160.86, indicating a 51.4% undervaluation. TARS has a GF Score™ of 46/100, reflecting mixed financial health and performance. The company focuses on biotechnology, particularly eye care, with its lead product being XDEMVY.
2 min readTarsus Pharmaceuticals, Inc. (TARS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care September 4, 2026 Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disease, a pote
2 min readAzamian Bobak R. (President/CEO and Board Chair) sold 10,000 indirectly-held shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $90.56 ($90.27–$91.27, $0.91M total) across 2 trades on 2026-09-04 under a Rule 10b5-1 trading plan.
1 min readLin Elizabeth Yeu (Chief Medical Officer) sold 10,773 shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $87.50 ($85.00–$90.00, $0.94M total) across 2 trades on 2026-09-04 under a Rule 10b5-1 trading plan.
1 min readJefferies raised its price target on Tarsus Pharmaceuticals (NASDAQ:TARS) to $105, citing strong guidance and recent prescription data. The stock has surged 23% in the past week. Tarsus reported Q2 2026 sales of $173.9M, beating expectations, and raised full-year sales guidance for XDEMVY. The company has a market cap of approximately $4B and is considered undervalued by InvestingPro analysis.
2 min readTarsus Pharmaceuticals (TARS) completed its acquisition of Alkeus Pharmaceuticals, gaining worldwide rights to ALK-001, a Phase 3 investigational therapy for Stargardt disease. ALK-001 has received multiple FDA designations and is expected to report topline data in 2029. The acquisition expands Tarsus' pipeline and supports its eye care strategy. TARS shares closed at $83.21 on Thursday, up 0.54%.
2 min read
